https://zora.fi/blog/2016/05/06/plasma-ceramides-predict-cardiovascular-death-in-patients-with-stable-coronary-artery-disease-and-acute-coronary-syndromes-beyond-ldl-cholesterol/2016-05-17T09:11:41+03:00https://zora.fi/blog/2016/05/06/389/2016-05-06T17:22:48+03:00https://zora.fi/blog/2016/04/06/plasma-concentrations-of-molecular-lipid-species-in-relation-to-coronary-plaque-characteristics-and-cardiovascular-outcome-results-of-the-atheroremo-ivus-study/2016-05-16T09:11:57+03:00https://zora.fi/blog/2016/04/08/stomping-forward-statins-muscle-complaints-and-ck/2016-05-16T09:10:53+03:00https://zora.fi/blog/2016/04/06/identifying-new-risk-markers-and-potential-targets-for-coronary-artery-disease-the-value-of-the-lipidome-and-metabolome/2016-05-16T09:11:38+03:00https://zora.fi/blog/2016/05/05/accumulated-metabolites-of-hydroxybutyric-acid-serve-as-diagnostic-and-prognostic-biomarkers-of-ovarian-high-grade-serous-carcinomas/2016-05-16T09:10:09+03:00https://zora.fi/blog/2016/04/02/molecular-lipids-identify-cardiovascular-risk-and-are-efficiently-lowered-by-simvastatin-and-pcsk9-deficiency/2016-05-16T09:12:26+03:00https://zora.fi/blog/2016/04/06/beyond-ldl-c-lowering-distinct-molecular-sphingolipids-are-good-indicators-of-proprotein-convertase-subtilisinkexin-type-9-pcsk9-deficiency/2016-05-16T09:11:19+03:00https://zora.fi/blog/2016/04/08/lipidomics-in-drug-discovery/2016-05-16T09:09:51+03:00https://zora.fi/blog/2016/05/03/lipidomics-a-tool-for-studies-of-atherosclerosis/2016-05-16T09:10:31+03:00https://zora.fi/blog/2016/03/28/alcohol-produces-distinct-hepatic-lipidome-and-eicosanoid-signature-in-lean-and-obese/2016-05-16T09:12:54+03:00https://zora.fi/blog/2016/03/06/fish-oil-and-krill-oil-differentially-modify-the-liver-and-brain-lipidome-when-fed-to-mice/2016-05-16T09:13:59+03:00https://zora.fi/blog/2016/03/10/rna-seq-and-mass-spectrometry-based-lipidomics-reveal-extensive-changes-of-glycerolipid-pathways-in-brown-adipose-tissue-in-response-to-cold/2016-05-16T09:13:39+03:00https://zora.fi/blog/2016/05/11/new-biomarker-for-identification-of-coronary-artery-disease-patients-at-high-risk-for-cardiovascular-death/2016-05-13T12:02:24+03:00https://zora.fi/blog/2016/04/12/development-and-validation-of-a-high-throughput-lc-msms-assay-for-routine-measurement-of-molecular-ceramides/2016-05-12T14:42:07+03:00https://zora.fi/blog/2016/03/12/long-term-performance-and-stability-of-molecular-shotgun-lipidomic-analysis-of-human-plasma-samples/2016-05-16T09:13:17+03:00https://zora.fi/blog/2016/05/24/zora-at-nature-reviews-research-highlights/2016-05-25T10:15:02+03:00https://zora.fi/blog/2016/05/30/zora-at-eas-2016-innsbruck/2016-05-30T16:39:53+03:00https://zora.fi/blog/2016/06/01/zora-and-mayo-medical-laboratories-to-collaborate-on-plasma-ceramide-testing/2016-06-01T14:47:25+03:00https://zora.fi/blog/2016/08/03/plasma-ceramide-test-is-now-available-at-mayo-clinic-medical-laboratories/2016-08-03T10:34:14+03:00https://zora.fi/blog/2016/09/05/we-are-hiring-join-zora-team/2016-09-06T08:19:12+03:00https://zora.fi/blog/2016/10/28/circulating-ceramides-predict-cardiovascular-outcomes-in-the-population-based-finrisk-2002-cohort/2016-10-28T14:05:04+03:00https://zora.fi/blog/2016/10/17/sydankohtausriskitesti-saatavilla-yhtyneet-medix-laboratorioiden-kautta/2016-11-22T14:41:59+02:00https://zora.fi/blog/2016/11/22/heart-attack-risk-test-cert-is-available-from-various-medical-centers-in-finland/2017-03-21T15:27:24+02:00https://zora.fi/blog/2017/01/16/what-are-plasma-ceramides/2017-03-02T14:55:20+02:00https://zora.fi/blog/2017/03/17/mayo-clinic-will-present-plasma-ceramide-results-acc-2017/2017-03-17T13:38:01+02:00https://zora.fi/blog/2017/03/21/zora-ceramides-science-daily/2017-03-24T17:30:07+02:00https://zora.fi/blog/2017/05/08/plasma-ceramides-highlighted-european-heart-journal/2017-05-08T15:51:10+03:00https://zora.fi/blog/2018/01/03/press-release-zora-announces-cert-validated-test-cardiovascular-diabetes-risk-prediction/2018-01-03T14:36:35+02:00https://zora.fi/blog/2018/01/08/new-generation-lipid-test-ceramides-new-cholesterol/2018-01-30T15:29:56+02:00https://zora.fi/blog/2018/01/30/high-grade-ovarian-serous-carcinoma-patients-exhibit-profound-alterations-lipid-metabolism/2018-01-30T15:35:48+02:00https://zora.fi/blog/2018/02/01/pcsk9-inhibition-alters-lipidome-plasma-lipoprotein-fractions/2018-02-01T10:28:39+02:00https://zora.fi/blog/2018/03/15/ceramide-stearic-palmitic-acid-ratio-predicts-incident-diabetes/2018-03-15T11:00:55+02:00https://zora.fi/blog/2018/06/06/zora-participates-xxxvi-nordic-congress-clinical-chemistry-congress-june-helsinki/2018-06-06T10:45:14+03:00https://zora.fi/blog/2018/08/08/plasma-concentrations-molecular-lipid-species-predict-long-term-clinical-outcome-coronary-artery-disease-patients/2018-08-08T12:51:38+03:00https://zora.fi/blog/2018/08/28/susceptibility-of-low-density-lipoprotein-particles-to-aggregate-depends-on-particle-lipidome-is-modifiable-and-associates-with-future-cardiovascular-deaths/2018-08-28T10:36:12+03:00https://zora.fi/blog/2019/02/01/zora-brings-molecular-lipids-to-the-clinic-for-cardiovascular-risk-prediction-with-enhanced-capacity/2019-02-01T15:31:51+02:00https://zora.fi/blog/2019/02/19/zora-biosciences-pushing-ceramide-testing-to-assess-cardiovascular-risk/2019-02-19T09:03:56+02:00https://zora.fi/blog/2019/06/18/development-and-validation-of-a-ceramide-and-phospholipid-based-cardiovascular-risk-estimation-score-for-coronary-artery-disease-patients/2019-06-18T09:03:46+03:00https://zora.fi/blog/2019/06/24/ldl-cholesterol-does-not-predict-heart-risk-among-heart-patients/2019-06-24T14:16:50+03:00https://zora.fi/blog/2020/05/12/prediction-of-residual-risk-by-ceramide%e2%80%90phospholipid-score-in-patients-with-stable-coronary-heart-disease-on-optimal-medical-therapy/2020-05-12T09:23:38+03:00https://zora.fi/blog/2020/05/12/zora-is-part-of-major-european-heart-disease-prevention-project/2020-05-12T12:06:52+03:00https://zora.fi/blog/2021/02/02/plasma-ceramide-and-phospholipid-based-risk-score-and-the-risk-of-cardiovascular-death-in-patients-after-acute-coronary-syndrome/2021-09-01T11:01:58+03:00https://zora.fi/blog/2020/10/02/ceramides-improve-atherosclerotic-cardiovascular-disease-risk-assessment-beyond-standard-risk-factors/2021-09-01T11:02:12+03:00https://zora.fi/blog/2020/09/02/ceramides-and-ceramide-scores-clinical-applications-for-cardiometabolic-risk-stratification/2021-09-01T11:02:23+03:00https://zora.fi/blog/2020/06/02/associations-between-specific-plasma-ceramides-and-severity-of-coronary-artery-stenosis-assessed-by-coronary-angiography/2021-09-01T11:02:35+03:00https://zora.fi/blog/2021/03/15/zora-biosciences-licenses-ceramide-technology-to-quest-diagnostics-for-cardiovascular-mortality-prediction-test/2021-03-15T15:51:35+02:00https://zora.fi/blog/2021/04/09/a-novel-two-lipid-signature-is-a-strong-and-independent-prognostic-factor-in-ovarian-cancer/2021-09-01T11:01:40+03:00https://zora.fi/blog/2021/08/30/prior-myocardial-infarction-coronary-artery-disease-extent-diabetes-mellitus-and-cert2-score-for-risk-stratification-in-stable-coronary-artery-disease/2021-09-01T11:00:52+03:00https://zora.fi/blog/2021/07/14/absolute-and-relative-risk-prediction-in-cardiovascular-primary-prevention-with-a-modified-score-chart-incorporating-ceramide-phospholipid-risk-score-and-diabetes-mellitus/2021-09-01T11:01:14+03:00https://zora.fi/blog/2021/08/22/comparison-of-recent-ceramide-based-coronary-risk-prediction-scores-in-cardiovascular-disease-patients/2021-09-01T11:00:39+03:00https://zora.fi/blog/2021/06/05/primary-cardiovascular-risk-prediction-by-ldl-cholesterol-in-caucasian-middle-aged-and-older-adults-a-joint-analysis-of-three-cohorts/2021-09-01T11:01:26+03:00https://zora.fi/blog/2021/09/07/invitation-to-the-annual-general-meeting/2021-09-07T12:46:39+03:00https://zora.fi/blog/2022/06/07/invitation-to-the-annual-general-meeting-2/2022-06-07T12:42:34+03:00https://zora.fi/blog/2022/07/22/plasma-ceramides-independently-predict-all-cause-mortality-in-men-aged-85/2023-03-23T10:14:41+02:00https://zora.fi/blog/2023/01/23/ceramides-and-phosphatidylcholines-associate-with-cardiovascular-diseases-in-the-elderly/2023-03-23T10:16:59+02:00https://zora.fi/blog/2024/02/01/ceramides-improve-cardiovascular-risk-prediction-beyond-low-density-lipoprotein-cholesterol/2024-02-01T14:27:39+02:00https://zora.fi/blog/2024/02/01/ceramides-improve-cardiovascular-risk-prediction-beyond-low-density-lipoprotein-cholesterol-2/2024-02-01T15:10:40+02:00https://zora.fi/blog/2024/02/07/straight-from-the-heart-lipids-called-ceramides-may-be-better-predictors-of-cardiovascular-problems-than-cholesterol-doctors-and-pharma-are-waking-up-to-their-potential/2024-02-15T16:33:23+02:00https://zora.fi/blog/2025/08/15/invitation-to-the-annual-general-meeting-3/2025-08-25T13:35:20+03:00https://zora.fi/blog/2025/11/28/learn-how-mayo-clinic-uses-cert-test/2025-11-28T11:31:26+02:00https://zora.fi/blog/2026/01/26/invitation-to-the-extraordinary-general-meeting/2026-01-29T15:54:49+02:00https://zora.fi/blog/2026/06/04/invitation-to-annual-general-meeting/2026-06-04T11:02:21+03:00